{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:14:58Z","timestamp":1792610098916,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"biomarin pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The objective of this study was to describe clinical manifestations and events of patients with mucopolysaccharidosis (MPS) VI in Turkey who are treated with galsulfase enzyme replacement therapy (ERT). Clinical data of 14 children with MPS VI who were followed up at the Department of Pediatrics of the Gazi University Faculty of Medicine in Ankara, Turkey were retrospectively collected from the patients\u2019 medical records. Patients were selected based on availability of a pre-ERT baseline and follow-up clinical data for a similar period of time (1.9\u20133.2\u00a0years). Event data (occurrence of acute clinical events, onset of chronic events, surgeries) collected during hospital visits and telemedicine were available for up to 10\u00a0years after initiation of ERT (2.5\u201310\u00a0years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Age at initiation of ERT ranged from 2.8 to 15.8\u00a0years (mean age 7.5\u00a0years). All patients presented with reduced endurance and skeletal abnormalities (dysostosis multiplex) on radiography. Other common clinical manifestations were cardiac valve disease (N\u2009=\u200913), short stature (N\u2009=\u200911), cranial abnormalities on MRI (N\u2009=\u200910), spinal abnormalities on MRI (N\u2009=\u20097), and mild cognitive impairment (N\u2009=\u20096). School attendance was generally poor, and several patients had urinary incontinence. After 1.9 to 3.2\u00a0years of ERT, most patients showed improvements in endurance in the 6-min walk test and 3-min stair climb tests; the frequency of urinary incontinence decreased. ERT did not seem to prevent progression of cardiac valve disease, eye disorders, hearing loss, or bone disease. Long-term event-based data showed a high incidence of respiratory tract infections, adenotonsillectomy\/adenoidectomy, reduced sleep quality, sleep apnea, and depression before initiation of ERT. The number of events tended to remain stable or decrease in all patients over 2.5\u201310\u00a0years follow-up. However, the nature of the events shifted over time, with a reduction in the frequency of respiratory tract infections and sleep problems and an increase in ophthalmologic events, ear tube insertions, and depression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This case series shows the high disease burden of the MPS VI population in Turkey and provides a unique insight into their clinical journey based on real-life clinical and event-based data collected before and after initiation of ERT.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-021-02060-4","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T11:21:29Z","timestamp":1634642489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series"],"prefix":"10.1186","volume":"16","author":[{"given":"Asl\u0131","family":"\u0130nci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lyas","family":"Okur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"T\u00fcmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcrsel","family":"Bibero\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"\u00d6ktem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-3118","authenticated-orcid":false,"given":"Fatih","family":"Ezg\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"2060_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2741\/4490","volume":"21","author":"PR Harmatz","year":"2017","unstructured":"Harmatz PR, Shediac R. Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment. Front Biosci. 2017;21:385\u2013406.","journal-title":"Front Biosci"},{"key":"2060_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1750-1172-5-5","volume":"5","author":"V Valayannopoulos","year":"2010","unstructured":"Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010;5:5.","journal-title":"Orphanet J Rare Dis"},{"key":"2060_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10545-011-9410-9","volume":"36","author":"CJ Hendriksz","year":"2013","unstructured":"Hendriksz CJ, Giugliani R, Harmatz P, Lampe C, Martins AM, Pastores GM, Steiner RD, Le\u00e3o Teles E, Valayannopoulos V. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis. 2013;36:373\u201384.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 5","key":"2060_CR4","doi-asserted-by":"publisher","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2011","unstructured":"Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v4\u201312.","journal-title":"Rheumatology (Oxford)"},{"key":"2060_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13052-018-0551-4","volume":"44","author":"M Rigoldi","year":"2018","unstructured":"Rigoldi M, Verrecchia E, Manna R, Mascia MT. Clinical hints to diagnosis of attenuated forms of mucopolysaccharidoses. Ital J Pediatr. 2018;44:132.","journal-title":"Ital J Pediatr"},{"key":"2060_CR6","doi-asserted-by":"crossref","unstructured":"Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, Borgo A, Braunlin E, Eto Y, Gold JI, Jester A, Jones SA, Karsli C, Mackenzie W, Marinho DR, McFadyen A, McGill J, Mitchell JJ, Muenzer J, Okuyama T, Orchard PJ, Stevens B, Thomas S, Walker R, Wynn R, Giugliani R, Harmatz P, Hendriksz C, Scarpa M, Committee MPSCPS, Co-Chairs MPSCP. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14:118.","DOI":"10.1186\/s13023-019-1080-y"},{"key":"2060_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1542\/peds.2006-2184","volume":"120","author":"R Giugliani","year":"2007","unstructured":"Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007;120:405\u201318.","journal-title":"Pediatrics"},{"key":"2060_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.2174\/138920111795542688","volume":"12","author":"R Giugliani","year":"2011","unstructured":"Giugliani R, Carvalho CG, Herber S, de Camargo Pinto LL. Recent advances in treatment approaches of mucopolysaccharidosis VI. Curr Pharm Biotechnol. 2011;12:956\u201362.","journal-title":"Curr Pharm Biotechnol"},{"key":"2060_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","volume":"94","author":"P Harmatz","year":"2008","unstructured":"Harmatz P, Giugliani R, Schwartz IVD, Guffon N, Teles EL, Miranda MCS, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Yu ZF, Swiedler SJ, Decker C. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94:469\u201375.","journal-title":"Mol Genet Metab"},{"key":"2060_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","volume":"33","author":"P Harmatz","year":"2010","unstructured":"Harmatz P, Yu ZF, Giugliani R, Schwartz IVD, Guffon N, Teles EL, S\u00e1 Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Swiedler SJ, Hardy K, Berger KI, Decker C. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis. 2010;33:51\u201360.","journal-title":"J Inherit Metab Dis"},{"key":"2060_CR11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","volume":"144","author":"P Harmatz","year":"2004","unstructured":"Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B, Kaplan P, Simon J, Butensky E, Hopwood JJ. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144:574\u201380.","journal-title":"J Pediatr"},{"key":"2060_CR12","doi-asserted-by":"publisher","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"P Harmatz","year":"2005","unstructured":"Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, Yu ZF, Swiedler SJ, Hopwood JJ. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681\u20139.","journal-title":"Pediatrics"},{"key":"2060_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"P Harmatz","year":"2006","unstructured":"Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, S\u00e1 Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Yu ZF, Wittes J, Berger KI, Newman MS, Lowe AM, Kakkis E, Swiedler SJ. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533\u20139.","journal-title":"J Pediatr"},{"key":"2060_CR14","unstructured":"Pyle SI, Waterhouse AM, Greulich, WW. A radiographic standard of reference for the growing hand and wrist. Chicago: Press of Case Western University, (Yearbook Medical Publishers); 1971."},{"key":"2060_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4274\/jcrpe.2183","volume":"7","author":"O Neyzi","year":"2015","unstructured":"Neyzi O, Bundak R, G\u00f6k\u00e7ay G, G\u00fcn\u00f6z H, Furman A, Darendeliler F, Ba\u015f F. Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol. 2015;7:280\u201393.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"2060_CR16","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1002\/ajmg.a.36489","volume":"164A","author":"PN Kantaputra","year":"2014","unstructured":"Kantaputra PN, Kayserili H, Guven Y, Kantaputra W, Balci MC, Tanpaiboon P, Tananuvat N, Uttarilli A, Dalal A. Clinical manifestations of 17 patients affected with mucopolysaccharidosis type VI and eight novel ARSB mutations. Am J Med Genet A. 2014;164A:1443\u201353.","journal-title":"Am J Med Genet A"},{"key":"2060_CR17","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/humu.23613","volume":"39","author":"R Tomanin","year":"2018","unstructured":"Tomanin R, Karageorgos L, Zanetti A, Al-Sayed M, Bailey M, Miller N, Sakuraba H, Hopwood JJ. Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene. Hum Mutat. 2018;39:1788\u2013802.","journal-title":"Hum Mutat"},{"key":"2060_CR18","first-page":"1","volume":"18","author":"A Quartel","year":"2015","unstructured":"Quartel A, Hendriksz CJ, Parini R, Graham S, Lin P, Harmatz P. Growth charts for individuals with mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome). JIMD Rep. 2015;18:1\u201311.","journal-title":"JIMD Rep"},{"key":"2060_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/adc.2007.123653","volume":"93","author":"AE Lammers","year":"2008","unstructured":"Lammers AE, Hislop AA, Flynn Y, Haworth SG. The 6-minute walk test: normal values for children of 4\u201311 years of age. Arch Dis Child. 2008;93:464\u20138.","journal-title":"Arch Dis Child"},{"key":"2060_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1164\/rccm.200607-883OC","volume":"176","author":"AM Li","year":"2007","unstructured":"Li AM, Yin J, Au JT, So HK, Tsang T, Wong E, Fok TF, Ng PC. Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med. 2007;176:174\u201380.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 5","key":"2060_CR21","doi-asserted-by":"publisher","first-page":"v26","DOI":"10.1093\/rheumatology\/ker393","volume":"50","author":"KK White","year":"2011","unstructured":"White KK. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v26\u201333.","journal-title":"Rheumatology (Oxford)"},{"key":"2060_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10545-013-9649-4","volume":"37","author":"C Kampmann","year":"2014","unstructured":"Kampmann C, Lampe C, Whybra-Tr\u00fcmpler C, Wiethoff CM, Mengel E, Arash L, Beck M, Miebach E. Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy. J Inherit Metab Dis. 2014;37:269\u201376.","journal-title":"J Inherit Metab Dis"},{"key":"2060_CR23","doi-asserted-by":"crossref","unstructured":"Silveira M, Buriti AKL, Martins AM, Gil D, Azevedo MF. Audiometric evaluation in individuals with mucopolysaccharidosis. Clinics (Sao Paulo). 2018;73:e523.","DOI":"10.6061\/clinics\/2018\/e523"},{"key":"2060_CR24","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/ajmg.a.33902","volume":"155A","author":"A John","year":"2011","unstructured":"John A, Fagondes S, Schwartz I, Azevedo AC, Barrios P, Dalcin P, Menna-Barreto S, Giugliani R. Sleep abnormalities in untreated patients with mucopolysaccharidosis type VI. Am J Med Genet A. 2011;155A:1546\u201351.","journal-title":"Am J Med Genet A"},{"key":"2060_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.braindev.2013.07.016","volume":"36","author":"F Borlot","year":"2014","unstructured":"Borlot F, Arantes PR, Quaio CR, Franco JFDS, Lourenco CM, Bertola DR, Kim CA. New insights in mucopolysaccharidosis type VI: neurological perspective. Brain Dev. 2014;36:585\u201392.","journal-title":"Brain Dev"},{"key":"2060_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10545-012-9559-x","volume":"36","author":"ACM Azevedo","year":"2013","unstructured":"Azevedo ACM, Artigal\u00e1s O, Vedolin L, Koml\u00f3s M, Pires A, Giugliani R, Schwartz IVD. Brain magnetic resonance imaging findings in patients with mucopolysaccharidosis VI. J Inherit Metab Dis. 2013;36:357\u201362.","journal-title":"J Inherit Metab Dis"},{"key":"2060_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10545-015-9895-8","volume":"39","author":"BJ Ebbink","year":"2016","unstructured":"Ebbink BJ, Brands MM, van den Hout JM, Lequin MH, Coebergh van den Braak RR, van de Weitgraven RL, Plug I, Aarsen FK, van der Ploeg AT. Long-term cognitive follow-up in children treated for Maroteaux-Lamy syndrome. J Inherit Metab Dis. 2016;39:285\u201392.","journal-title":"J Inherit Metab Dis"},{"key":"2060_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12887-020-02484-0","volume":"21","author":"Z Ge","year":"2021","unstructured":"Ge Z, Mao J, Shen H, Xu Y, Fu H, Zhang W, Li D. Clinical and genetic characteristics of concomitant mucopolysaccharidosis type IVA and neurogenic bladder in children: two case reports and literature review. BMC Pediatr. 2021;21:18.","journal-title":"BMC Pediatr"},{"key":"2060_CR29","doi-asserted-by":"crossref","unstructured":"Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, Kronenberg MW, Kostis JB, Kohn RM, Guillotte M, Greenberg B, Woods PA, Bourassa MG, SOLVD Investigators. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA. 1993;270:1702\u20131707.","DOI":"10.1001\/jama.270.14.1702"},{"key":"2060_CR30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0002-9149(01)01975-0","volume":"88","author":"MR Shah","year":"2001","unstructured":"Shah MR, Hasselblad V, Gheorghiade M, Adams KF Jr, Swedberg K, Califf RM, O\u2019Connor CM. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol. 2001;88:987\u201393.","journal-title":"Am J Cardiol"},{"key":"2060_CR31","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/ajmg.a.36584","volume":"164A","author":"R Giugliani","year":"2014","unstructured":"Giugliani R, Lampe C, Guffon N, Ketteridge D, Le\u00e3o-Teles E, Wraith JE, Jones SA, Piscia-Nichols C, Lin P, Quartel A, Harmatz P. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)-10-year follow-up of patients who previously participated in an MPS VI survey study. Am J Med Genet A. 2014;164A:1953\u201364.","journal-title":"Am J Med Genet A"},{"key":"2060_CR32","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.3390\/ijms21082975","volume":"21","author":"R Parini","year":"2020","unstructured":"Parini R, Deodato F. Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations. Int J Mol Sci. 2020;21:2975.","journal-title":"Int J Mol Sci"},{"key":"2060_CR33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","volume":"77","author":"JJ McGill","year":"2010","unstructured":"McGill JJ, Inwood AC, Coman DJ, Lipke ML, de Lore D, Swiedler SJ, Hopwood JJ. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age - a sibling control study. Clin Genet. 2010;77:492\u20138.","journal-title":"Clin Genet"},{"key":"2060_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ymgmr.2017.08.007","volume":"13","author":"M Furujo","year":"2017","unstructured":"Furujo M, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up. Mol Genet Metab Rep. 2017;13:69\u201375.","journal-title":"Mol Genet Metab Rep"},{"key":"2060_CR35","first-page":"7","volume":"15","author":"JF Franco","year":"2016","unstructured":"Franco JF, Soares DC, Torres LC, Leal GN, Cunha MT, Honjo RS, Bertola DR, Kim CA. Impact of early enzyme-replacement therapy for mucopolysaccharidosis VI: results of a long-term follow-up of Brazilian siblings. Genet Mol Res. 2016;15:7.","journal-title":"Genet Mol Res"},{"key":"2060_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/ajmg.a.30579","volume":"134A","author":"SJ Swiedler","year":"2005","unstructured":"Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, Wraith JE, Roberts J, Ketteridge D, Hopwood JJ, Guffon N, S\u00e1 Miranda MC, Teles EL, Berger KI, Piscia-Nichols C. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet. 2005;134A:144\u201350.","journal-title":"Am J Med Genet"},{"key":"2060_CR37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/jimd.12079","volume":"42","author":"PR Harmatz","year":"2019","unstructured":"Harmatz PR, Lampe C, Parini R, Sharma R, Teles EL, Johnson J, Sivam D, Sisic Z. Enzyme replacement therapy outcomes across the disease spectrum: findings from the mucopolysaccharidosis VI clinical surveillance program. J Inherit Metab Dis. 2019;42:519\u201326.","journal-title":"J Inherit Metab Dis"},{"key":"2060_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cca.2016.11.015","volume":"464","author":"K El Moustafa","year":"2017","unstructured":"El Moustafa K, Sivri S, Karahan S, Co\u015fkun T, Akb\u0131y\u0131k F, Lay \u0130. Screening for mucopolysaccharidoses in the Turkish population: Analytical and clinical performance of an age-range specific, dye-based, urinary glycosaminoglycan assay. Clin Chim Acta. 2017;464:72\u20138.","journal-title":"Clin Chim Acta"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-02060-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T10:47:19Z","timestamp":1699699639000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-02060-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2060"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-02060-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"29 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Gazi University Faculty of Medicine Ethics Committee; approval date: April 13 2020; approval number 262. All patients provided consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided consent to publish clinical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"438"}}